FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy
Karyopharm Therapeutics has just announced that Eltanexor, their investigative therapy for myelodysplastic syndromes (MDS), has been given Orphan Drug Designation by the FDA. This designation means that the FDA believes…
Continue Reading
FDA Orphan Drug Designation Awarded to a Myelodysplastic Syndromes Investigative Therapy
